Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: bmaz001 who wrote (2166)	5/21/2013 11:36:10 AM
From: geneguru	Read Replies (2) \| Respond to of 2344

Maz -- ONTY is a risky investment for sure. That being said -- I find the START results stunning: 10 month+ MS advantage in the cCRT 65% Super Majority, p=.016. Maybe Rick or others can identify other cancer drugs with longer life extensions. I haven't found any. The sCRT "arm" is throwaway, and that technology will never again be used in any trial. Will FDA approve? Hard call. But a Merck filing probably would double or triple stock. A favorable Advisory Committee vote could double it again. Rick over here knows about as much as anybody. Good two-sided discussion going on over at the free Investors Village message board. Y!MB useless. Steve